Augtyro (repotrectinib)

Augtyro (repotrectinib) is a kinase inhibitor indicated for the treatment of:

• adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
• adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, have progressed following treatment or have no satisfactory alternative therapy. 

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Recommended Dosage:
The recommended dosage of Augtyro for adult patients and pediatric patients aged 12 years and older is 160 mg administered orally once daily for the first 14 days. Following this initial treatment period, the dosage should be increased to 160 mg administered orally twice daily. Treatment should be continued until disease progression or the occurrence of unacceptable toxicity. Augtyro may be taken with or without food and should be administered at approximately the same time each day.

Capsules must be swallowed whole. Do not open, crush, chew, or dissolve the capsules prior to administration. Capsules that are broken, cracked, or otherwise damaged should not be used. If a dose is missed, or if vomiting occurs after dose administration, the patient should not take an additional dose. The next dose should be taken at the regularly scheduled time.

• Rare cases of interstitial lung disease or pneumonitis may occur. Watch for new or worsening cough, shortness of breath, or fever. Stop treatment and seek medical attention if breathing problems occur. Early evaluation helps prevent serious complications.
• Dizziness, confusion, and seizures have been reported in some patients taking this medication. You should monitor for unusual behavior and changes in mental state. If any symptoms develop, do not drive or operate any kind of machinery. If worsening neurological symptoms develop, tell your doctor right away.
• Liver injury may occur while receiving treatment. Regular liver function tests are required. Symptoms may include fatigue, dark urine, yellowing of the skin or eyes, or abdominal pain. Contact your clinician immediately if signs or symptoms of liver problems appear.
• Tenderness, muscle pain, or weakness may develop, sometimes accompanied by elevated creatine phosphokinase (CPK) levels. Report unexplained muscle discomfort promptly. Your doctor may monitor blood tests and adjust treatment if muscle injury is suspected.
• This medicine may increase the risk of uric acid levels in the blood, leading to hyperuricemia or gout. Monitor for joint pain, swelling, or redness. Periodic blood tests may be required, especially in patients with a history of gout.
• Your treatment may put you at a slightly higher risk for bone fractures. Those with osteoporosis or other conditions that weaken bones should be particularly careful. Tell your doctor if you have a history of fractures or pain in your bones. You may need to increase your calcium and vitamin D intake.
• This medicine could harm your baby. Do not take this medicine during your pregnancy, unless it is necessary. Women who could become pregnant must use birth control during this treatment, and should contact their doctor if they become pregnant.
• It is not known whether this medicine passes into human breast milk. Breastfeeding is generally not recommended during treatment. Discuss risks and benefits with your healthcare provider to determine the safest feeding option for your baby.

What documents are required to import AUGTYRO to India?

AUGTYRO (repotrectinib) capsules can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is AUGTYRO available in India?

AUGTYRO (repotrectinib capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Augtyro in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Augtyro price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

AUGTYRO can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of AUGTYRO (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9810469557 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Augtyro cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Augtyro®?

Repotrectinib is the Generic Name for the trade name drug Augtyro®.

What is the Manufacturer’s Name of Augtyro®?

Augtyro® is manufactured by Bristol Myers Squibb (BMS).

Is Augtyro approved by the FDA?

Yes. Augtyro is approved by the FDA. Date of first approval: November 15, 2023.

What is the dosage and form of Augtyro® supplied?

Augtyro is supplied as Capsules: 40 mg, 160 mg of Repotrectinib for oral use.

What are the most common side effects of Augtyro® Capsules?

The most commonly reported side effects of Augtyro® are dizziness, peripheral neuropathy, constipation, dysgeusia, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, and nausea.

How does Augtyro Import in India work?

Augtyro import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

How much does Augtyro® Capsule cost in India?

Augtyro® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Augtyro prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Augtyro cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Augtyro® Capsules be available in SAARC countries?

Apart from Gulf countries, Augtyro® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Augtyro® Capsules in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Augtyro® Capsules online in India?

Yes, one can buy Augtyro in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Augtyro® Capsules through legal channels.

What are the storage conditions of Augtyro® Capsules?

Store the capsules at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).